| __timestamp | Dr. Reddy's Laboratories Limited | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 56369000000 | 9136000 |
| Thursday, January 1, 2015 | 62786000000 | 5807000 |
| Friday, January 1, 2016 | 62427000000 | 5571000 |
| Sunday, January 1, 2017 | 62453000000 | 5366000 |
| Monday, January 1, 2018 | 65724000000 | 6337000 |
| Tuesday, January 1, 2019 | 70421000000 | 11347000 |
| Wednesday, January 1, 2020 | 80591000000 | 30419000 |
| Friday, January 1, 2021 | 86645000000 | 62176000 |
| Saturday, January 1, 2022 | 100551000000 | 52827000 |
| Sunday, January 1, 2023 | 42907000000 | 35049000 |
| Monday, January 1, 2024 | 115557000000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Dr. Reddy's Laboratories Limited and Ligand Pharmaceuticals Incorporated offer a fascinating study in contrasts. Over the past decade, Dr. Reddy's has consistently managed a high cost of revenue, peaking at approximately $115.6 billion in 2024, reflecting its expansive operations. In contrast, Ligand Pharmaceuticals, with a more focused business model, reported a peak cost of revenue of around $62.2 million in 2021.
From 2014 to 2023, Dr. Reddy's cost of revenue grew by about 105%, while Ligand's increased by over 280%, albeit from a much smaller base. This disparity highlights the different scales and strategies of these companies. Notably, 2024 data for Ligand is missing, suggesting a potential shift or anomaly in reporting. This analysis underscores the diverse approaches to cost management in the pharmaceutical industry.
Comparing Cost of Revenue Efficiency: Sanofi vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Dr. Reddy's Laboratories Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Dr. Reddy's Laboratories Limited
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Incyte Corporation and Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.'s Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Galapagos NV